Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Tec...
April 10 2017 - 08:05AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (CBMG or the
Company), a leading clinical-stage biopharmaceutical firm engaged
in the development of immunotherapies for cancer and stem cell
therapies for degenerative diseases and GE Healthcare Life Sciences
China, today announced that they have established a strategic
research collaboration to co-develop certain high-quality
industrial control processes in Chimeric Antigen Receptor T-cell
(CAR-T) and stem cell manufacturing. In connection with the
collaboration, a joint laboratory within CBMG’s new Shanghai
Zhangjiang GMP-facility will be established and dedicated to the
joint research and development of a functionally integrated and
automated immunotherapy cell preparation system.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/ab5bc905-b526-4e86-98bd-c96e306b5796
CBMG and GE Healthcare Life Sciences China plan
to develop state-of-the-art automated CAR-T and stem cell
manufacturing capabilities that build upon the accreditation of
CBMG’s GMP facilities in Shanghai, Wuxi and Beijing. The
co-development activity will aim to standardize the delivery of
cell manufacturing to potentially improve throughput, alleviate
cost burdens and to minimize variability in cell production, which
may increase the availability of engineered cells upon
commercialization.
This partnership combines CBMG’s scientific
expertise in the manufacturing of CAR-T and stem cell production in
China and GE Healthcare’s renowned expertise in the design and
development of innovative manufacturing technologies for the
biopharmaceutical industry.
Recently, CBMG announced that its new Zhangjiang
facility, together with an expanded Wuxi, and Beijing
GMP-facilities, will have a combined 70,000 square feet for
development and production. This will enable CBMG to conduct
simultaneous clinical trials for multiple CAR-T and stem cell
product candidates. At full production volumes, these facilities
could support the treatment of up to 10,000 cancer patients and
10,000 knee osteoarthritis patients per year.
“GE Healthcare‘s selection of our facility
to serve as their showcase site in China, credits our GMP stature
and capabilities. Our team of scientists has spent years refining
our manufacturing process to become one of the very few cell
therapy companies with fully in-house integrated chemistry,
manufacturing, and controls (CMC) processes for clinical grade
CAR-T cells, plasmid and viral vectors bank production. We
understand that one of the impending barriers to adoption of
immuno-oncology and stem cell therapies is the logistics in
manufacturing and we look to take an expanded role both
domestically and potentially globally. We are pleased to be
in a strategic partnership with GE Healthcare and look forward to
showcasing our facilities and the mutual benefit this joint
laboratory will bring,” commented Tony Liu, Chief Executive
Officer, CBMG.
“Cell therapy as an industry continues to refine
and evolve in China with vast potential to change the ways various
diseases are treated. GE continues investing in technologies
and services aimed at the thriving cell therapy industry with a
firm commitment of making these promising therapies accessible
through successful industrialization. We are pleased to partner
with CBMG, a leader in CAR-T and stem cell development in China and
to take advantage of their excellent CMC cell production
capabilities. Collaboration with ambitious partners like CBMG who
share our vision is necessary for advancing innovation and
delivering comprehensive manufacturing solutions for cell and
regenerative medicines,” said Li Qing, General Manager, GE
Healthcare Life Sciences, Greater China.
About Cellular Biomedicine Group Cellular
Biomedicine Group, Inc. (NASDAQ:CBMG) develops proprietary cell
therapies for the treatment of cancer and degenerative diseases. We
conduct immuno-oncology and stem cell clinical trials in China
using products from our integrated GMP laboratory. Our GMP
facilities in China, consisting of twelve independent cell
production lines, are designed and managed according to both China
and U.S. GMP standards. CBMG recently commenced two Phase I
human clinical trials in China using CAR-T to treat
relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL)
and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an
ongoing Phase I trial in China for AlloJoinTM (CBMG’s
“Off-the-Shelf” Allogeneic Human Adipose-derived Mesenchymal Stem
Cell) for the treatment of Knee Osteoarthritis (KOA). CBMG was also
recently awarded $2.29 million from the California Institute for
Regenerative Medicine (CIRM) to support pre-clinical studies of
AlloJoinTM for Knee Osteoarthritis in the United States. To learn
more about CBMG, please visit www.cellbiomedgroup.com.
About GE Healthcare GE Healthcare provides
transformational medical technologies and services to meet the
demand for increased access, enhanced quality and more affordable
healthcare around the world. GE (NYSE:GE) works on things
that matter - great people and technologies taking on tough
challenges. From medical imaging, software & IT, patient
monitoring and diagnostics to drug discovery, biopharmaceutical
manufacturing technologies and performance improvement solutions,
GE Healthcare helps medical professionals deliver great healthcare
to their patients. For more information about GE Healthcare, visit
our website at www.gehealthcare.com.
Forward-Looking Statements This press release
contains forward-looking statements—including descriptions of
plans, strategies, trends, specific activities, investments and
other non-historical facts—as defined by the Private Securities
Litigation Reform Act of 1995, Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking information is inherently
uncertain, and actual results could differ materially from those
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy
(including the devaluation of the RMB by China in August 2015), and
other risks detailed in CBMG’s reports filed with the Securities
and Exchange Commission, quarterly reports on form 10-Q, current
reports on form 8-K and annual reports on form 10-K.
Forward-looking statements may be identified by terms such as
“may,” “will,” “expects,” “plans,” “intends,” “estimates,”
“potential,” “continue” or similar terms or their negations.
Although CBMG believes the expectations reflected in the
forward-looking statements are reasonable, they cannot guarantee
that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
The photo is also available at Newscom,
www.newscom.com, and via AP PhotoExpress.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Citigate Dewe Rogerson
+1 347 481-3711
vivian.chen@citigatedr.com
General Electric (NYSE:GE)
Historical Stock Chart
From Feb 2024 to Mar 2024
General Electric (NYSE:GE)
Historical Stock Chart
From Mar 2023 to Mar 2024